Top 10 Oncology Funding Leaders to Watch in H2 2026
Funding activity can reveal more than who raised the most money. It shows which technologies, disease areas, and development strategies are attracting capital—and where new clinical momentum may follow.
Using BiopharmIQ funding titles, we identified the 10 largest disclosed H2 2026 funding events explicitly connected to oncology, cancer, or tumors. All 10 companies are private.
The 2026 ADC watchlist
Solstice Oncology
Funding: $225M
Series A
Location: Boston, Massachusetts
Solstice is developing antibody therapies for solid tumors. Its lead program, porustobart, is an engineered heavy-chain-only CTLA-4 antibody being studied for neoadjuvant treatment of colon cancer.
2026 trial signal: No new 2026 clinical-trial entry is currently listed under Solstice in BiopharmIQ. The initiation or registration of the funded porustobart studies is therefore an important next signal to watch.
BrainChild Bio
Funding: $116M
Series A
Location: Seattle, Washington
BrainChild develops CAR-T therapies for pediatric central nervous system tumors, with an initial focus on diffuse intrinsic pontine glioma.
2026 trial signal: Yes. A pivotal Phase 2 study of BCB-276 in pediatric brain cancer was added in July 2026, directly connecting the financing with clinical execution.
Explore our clinical trial data →
Cloverleaf Bio
Funding: $33M
Seed financing
Location: New Haven, Connecticut
Cloverleaf is developing engineered tRNA therapeutics that exploit differences between tumor and healthy-cell biology. Its pipeline includes programs for liver and colorectal cancers.
2026 trial signal: No new clinical trial is listed in 2026. The company remains an early-stage platform story, making its first IND or clinical entry the key milestone to track.
N-Power Medicine
Funding: $32M
Series B
Location: Redwood City, California
N-Power operates an oncology research and data platform connecting community practices with biopharma sponsors. Its technology supports trial access, real-world data generation and precision external control arms.
2026 trial signal: No new 2026 trial entry was identified. Its most recent listed study was initiated in 2025 and focuses on external controls in advanced or metastatic NSCLC.
Craif
Funding: $24.53M
Series D
Location: Tokyo, Japan
Craif develops urine- and saliva-based molecular diagnostics for cancer detection. Its platform combines microRNA biomarkers, bioinformatics, and artificial intelligence.
2026 trial signal: No new clinical-trial entry is listed for 2026. Regulatory and clinical-validation progress, particularly for its pancreatic-cancer diagnostic, is the more relevant signal to monitor.
Immunophotonics
Funding: Initial $10M
Series C
Location: St. Louis, Missouri
Immunophotonics is developing IP-001, an immune-modulating polymer designed to turn tumor ablation into a systemically active cancer immunotherapy.
2026 trial signal: Yes. A new study was added in January to evaluate intratumoral IP-001 following liver-tumor ablation in patients with metastatic colorectal cancer.
Explore our clinical trial data →
Tikva Allocell
Funding: $8M
Series A
Location: Singapore
Tikva is developing allogeneic EBV-specific T-cell therapies. Its lead program, TAVST01, targets B7-H3-positive solid tumors.
2026 trial signal: No new 2026 clinical-trial entry was identified. The financing makes the program’s transition into clinical development the main upcoming signal.
IntraGel Therapeutics
Funding: Up to $7M
Strategic corporate investment
Location: Nazareth, Israel
IntraGel is developing SRGel, a solvent-free sustained-release platform for localized and systemic drug delivery. Its oncology work includes the localized TumoCure program.
2026 trial signal: No new clinical trial is currently listed. The next development step under its UroGen collaboration will be important for determining how quickly SRGel moves toward clinical testing.
DermaSensor
Funding: $5M
Series B
Location: Miami, Florida
DermaSensor has developed an FDA-cleared handheld device that combines elastic-scattering spectroscopy with AI to help primary-care physicians assess suspicious skin lesions.
2026 trial signal: No new 2026 trial was identified. BiopharmIQ lists an earlier clinical study evaluating physician use of the device, while the new funding is focused primarily on commercialization and adoption.
Intus Bio
Funding: $2.7M
NIH/NCI Fast-Track grant
Location: Farmington, Connecticut
Intus Bio applies high-resolution microbiome analysis and AI to identify bacterial biomarkers. The new award supports development of a bacteria-based test for early-onset colorectal cancer.
2026 trial signal: No new clinical trial is listed. This remains a diagnostic-development project, with analytical and clinical validation representing the next signals to watch.
Funding is one of the hottest signals to follow in biopharma. A new financing round often means a company is preparing to advance its pipeline, launch studies, expand its team, or invest in new partnerships and external capabilities, making it a timely opportunity for outreach.
Need help building a targeted prospect list of oncology companies with recent funding events? We can create a tailored list based on your preferred technologies, disease areas, locations, funding types, and other criteria.
BiopharmIQ MCP/API
By connecting specialized BiopharmIQ data directly to an AI workflow, MCP made it possible to screen companies, compare public and private players, examine supporting signals, and turn the results into a source-linked interactive dashboard.
The value is not simply generating another list. It is being able to explore life-sciences intelligence conversationally and rapidly transform the results into a practical research asset. Enjoy this dashboard, Create yours → Try Our MCP (Ask for 2 Full Free Weeks)
Article History:
09/21/26 MD
Comments